A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis

ClinicalTrials.gov ID: NCT00293917

Public ClinicalTrials.gov record NCT00293917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 19, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to assess the long-term safety of tacrolimus cream in the treatment of psoriasis

Study identification

NCT ID: NCT00293917
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Astellas Pharma Inc; Industry
Enrollment: 658 participants

Conditions and interventions

Conditions

Psoriasis

Interventions

Tacrolimus Cream Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2005
Primary completion: Jul 31, 2007
Completion: Jul 31, 2007
Last update posted: Feb 12, 2008

2006 – 2007

United States locations

U.S. sites: 31
U.S. states: 21
U.S. cities: 29

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	30322	—
Not listed	Fresno	California	93710	—
Not listed	Santa Monica	California	90404	—
Not listed	Vista	California	92083	—
Not listed	Jacksonville	Florida	32204	—
Not listed	Miami	Florida	—	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Newnan	Georgia	30263	—
Not listed	Boise	Idaho	83704	—
Not listed	Chicago	Illinois	60614	—
Not listed	Chicago	Illinois	—	—
Not listed	Louisville	Kentucky	40202	—
Not listed	New Orleans	Louisiana	70112	—
Not listed	Boston	Massachusetts	02118	—
Not listed	Detroit	Michigan	48202	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	Lincoln	Nebraska	68502	—
Not listed	Reno	Nevada	89511	—
Not listed	Lebanon	New Hampshire	03756	—
Not listed	East Windsor	New Jersey	08520	—
Not listed	East Setauket	New York	11733	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10025	—
Not listed	Hershey	Pennsylvania	17033	—
Not listed	Simpsonville	South Carolina	29681	—
Not listed	Goodlettsville	Tennessee	37072	—
Not listed	Arlington	Texas	76011	—
Not listed	Houston	Texas	77056	—
Not listed	Bellingham	Washington	98225	—
Not listed	Kenatchee	Washington	98801	—
Not listed	Spokane	Washington	99202	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00293917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 12, 2008 · Synced Sep 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00293917 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →